New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
13:36 EDTPBYIPuma presents 'positive' PB272 Phase II data from I-SPY 2 trial
Puma Biotechnology announced the presentation of "positive" results from the Phase II clinical trial of Puma's investigational drug PB272 for the neoadjuvant treatment of breast cancer, or I-SPY 2 trial, in an oral presentation. The presentation entitled “Neratinib plus Standard Neoadjuvant Therapy for High-Risk Breast Cancer: Efficacy Results from the I-SPY 2 TRIAL” was presented today at the session entitled “Clinical Trials Symposium: Biomarker Driven Clinical Trials.” The I-SPY 2 TRIAL is a randomized Phase II clinical trial for women with newly diagnosed Stage 2 or higher breast cancer that addresses whether adding investigational drugs to standard chemotherapy in the neoadjuvant setting is better than standard chemotherapy. The primary endpoint is pathological complete response in the breast and the lymph nodes at the time of surgery. The goal of the trial is to match investigational regimens with patient subsets on the basis of molecular characteristics that benefit from the regimen. The trial enrolled patients who had a high risk of relapse using up-front tumor profiling.
News For PBYI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 12, 2014
09:08 EDTPBYIPuma Biotechnology announces interim neratinib Phase II data
Subscribe for More Information
December 11, 2014
08:49 EDTPBYIPuma Biotechnology management to meet with UBS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use